Introduction
Rabbit haemorrhagic disease (RHD) is a highly infectious and fatal disease of the European rabbit (Oryctolagus cuniculus). It was first described in China (Liu et al., 1984) , then subsequently in most parts of the world affecting domestic rabbits and also wild populations. The etiological agent of the disease, the Rabbit hemorrhagic disease virus (RHDV), is a non-enveloped single-stranded positive-sense RNA virus belonging to the genus Lagovirus (Green et al., 2000) of the family Caliciviridae (Meyers et al., 1991; Ohlinger et al., 1990; Parra and Prieto, 1990; Rasschaert et al., 1995) .
Several works have serologically evidenced non-pathogenic RHDV-like strains in Europe (Capucci et al., 1997; Chasey et al., 1997; Marchandeau et al., 1998; Rodak et al., 1990; Trout et al., 1997) and also in Australia or New Zealand Nagesha et al., 2000; O'Keefe et al., 1999; Parkes et al., 2002; Robinson et al., 2002) . The existence of non-pathogenic RHDV strains was established in 1996, when a non-lethal RHDV-like strain genetically distinct from RHDV and called rabbit calicivirus (RCV) was isolated in a rabbitry in Italy (Capucci et al., 1996) . This strain differs from the RHDV by its tissue tropism, viral load and the sequence of the gene encoding the capsid protein. Subsequently, apparently non-pathogenic strains were detected after isolation of viral RNA fragments in healthy domestic or wild rabbits from the UK and Ireland (Forrester et al., 2007 (Forrester et al., , 2009 Moss et al., 2002) . Lastly, a recent report identified another non-pathogenic lagovirus named RCV-A1 in three apparently healthy young wild Australian rabbits (Strive et al., 2009 ). The Italian RCV and the Australian RCV-A1 are the only two viruses whose non-lethality has been experimentally confirmed (Capucci et al., 1996; Strive et al., 2010) . For all the other strains non-pathogenicity is assumed owing to their isolation in healthy non-vaccinated rabbits. A phylogenetic analysis of RHDV and genetically related non-pathogenic strains based on a fragment of the capsid protein nucleotide sequence showed three distinct genetic groups (Strive et al., 2009) . Besides the first group that contains RHDV strains, the second one contains RCV, the Lambay strain from Ireland, and the Ashington strain from the UK, and the third one contains Australian RCV-A1. These two last groups contain non-pathogenic strains except perhaps the Ashington strain, presumed to be a pathogenic virus although its pathogenicity has not been experimentally proved (Moss et al., 2002) . For the non-pathogenic viruses that are genetically related but relatively distant to pathogenic RHDV (i.e., the Italian RCV, the Irish Lambay strain, the English Ashington strain and the Australian RCV-A1) Kerr et al. (2009) proposed the name rabbit calicivirus-like (RCV-like) viruses to distinguish them from RHDV. However, since these viruses are all caliciviruses, it would be better to describe them as non-pathogenic rabbit calicivirus or lagovirus. In addition, a recent study suggested that as RCV and similar strains did not form a monophyletic group with RCV-A1, the name RCV-like was not appropriate for these viruses (Jahnke et al., 2010) . We have therefore chosen the name non-pathogenic lagovirus (NP-LV) to designate them.
Competition between non-pathogenic and pathogenic strains and the possible role of the non-pathogenic strains in reducing the impact of RHD have been discussed by several authors on the basis of cross-protection between strains (Boots et al., 2004; Cooke et al., 2000 Cooke et al., , 2002 Robinson et al., 2002; White et al., 2001 ). However, the protection conferred by antibodies induced by some NP-LV is lower than that conferred by antibodies induced by virulent RHDV or RCV Nagesha et al., 2000; Strive et al., 2010) . Otherwise, a French study based on serological data showed that antibodies produced in response to some NP-LV strains may not protect against RHDV (Marchandeau et al., 2005) . These results suggest that study of the competition between strains needs to take into account the existence of non-protective or slightly protective strains, which requires a sufficient knowledge of the diversity of the circulating strains.
In the present work, we have identified a new infectious lagovirus related to RHDV from healthy domestic rabbits and determined the sequence of the gene encoding the VP60 capsid protein in order to establish phylogenetic relationships with other rabbit lagoviruses. In addition, we have investigated its non-lethality for specific pathogen free (SPF) rabbits and the degree of cross-protection induced by the antibodies due to this viral strain against a lethal RHDV challenge.
Results

Serological status of the rabbits
The VP60-RHDV ELISA test performed on sera from 60 healthy 10-week-old rabbits from the rabbitry revealed that 38% of them were seropositive at D0 and 88% 1 week later, indicating that an active infection was in progress in the rabbitry (Table 1) . Sera from 24 rabbits seropositive at D6 and sacrificed for virological screening at D13 were tested with the cELISA and anti-isotype ELISA tests specific to RHDV. None were positive by cELISA, IgM, or IgA ELISA (b10), but some of them showed low levels of IgG (40-160) ( Table 1 ). According to Cooke et al. (2000) , these last rabbits (cELISA titres ≤ 10, with moderate IgG antibodies but without IgA or IgM) were considered to have been infected with a non-pathogenic lagovirus. Therefore, the antibodies detected with the VP60-RHDV ELISA test were not specific to pathogenic RHDV.
Sequence analysis of the capsid protein
Duodenum samples gave the first positive RT-PCR results when liver or spleen samples gave negative results. We therefore focused on duodenum samples to continue the search for viral RNA. Nineteen of the 29 duodenum intestines samples tested were positive and PCR product sequencing results confirmed that they were close to rabbit lagovirus sequences. Among the PCR-positive samples, sample JA1641 (strain 06-11) was subjected to a full-length VP60 PCR amplification and the PCR product was sequenced. 
*The rabbit number corresponds to the location where the rabbit was placed in quarantine ("AR" or "JA") followed by an order number. Numbers in italics and in bold correspond to the rabbits used for the experimental study of protection against RHDV challenge (five rabbits). A number in italics, in bold and underlined corresponds to the rabbits remained in the "JA" location that died from a natural RHD between D19 and D22 (9 rabbits). The number in a grey box (JA1641) corresponds to the rabbit from which the strain 06-11 was identified and characterised. † Serological status determined using VP60-RHDV ELISA. The scoring system is described in materials and methods section. ‡ The serum was also screened with competitive ELISA (cELISA) and anti-isotype ELISA tests (Capucci et al., 1997; Cooke et al., 2000; Lavazza and Capucci, 2008a) . b10: negative; 40-160: positive with a low titre. The corresponding rabbits were sacrificed at D13 for virological analysis (24 rabbits). § The rabbit were sacrificed at D21 for virological analysis (5 rabbits).
The 06-11 VP60 gene is 1734 nucleotides (nt) long (578 amino acids long) and when compared to RHDV, has a 6 nt deletion in length at position 921-927 which corresponds to the amino acids (aa) 308 and 309 of the VP60 protein of RHDV. A similar deletion is present at the same location in the Ashington strain genome and at aa 309 and 310 in the RCV genome. The average nucleotide identity between the VP60 gene sequences of 06-11 and RHDV is 83%. The 06-11 strain shared 85% identity with RCV but only 79% with the non-pathogenic RCV-A1. In contrast, this identity reached 93.8% with the Ashington sequence available in nucleotide databases (1542 nt/1644 nt identity).
The 06-11 VP60 deduced amino acid sequence was aligned with those of some RHDV reference strains including one antigenic variant RHDVa strain, RCV, Ashington and RCV-A1 (Fig. 1) . The average amino acid similarity between 06-11 and RHDV is 90.8%. It is 92.9% with RCV, 87% with RCV-A1 and 97.8% with the Ashington sequence. The majority of the 06-11 substitutions (83%) are located in the most variable part of the capsid protein, the C-terminal half. When we compared the sequences within the two regions that show the highest degree of genetic variation (region C from aa 301 to 310 and region E from aa 344 to 434, according to the nomenclature of Neill (1992) ), similarities decreased to about 81.2%, 79.2%, or 63.4%, between 06-11 and RHDV, RCV, or RCV-A1, respectively. These data emphasised the differences between the viruses. On the contrary, the similarity between the 06-11 and Ashington sequences reached 95%, and even 100% within the hypervariable region C which also contains the two amino acid deletions.
Genetic relationship
Irrespective of the method used, phylogenetic analyses implemented with the almost entire capsid protein nucleotide sequences of RCV-A1, 32 RHDV and RCV isolates gave similar results. They revealed that the rabbit lagoviruses were clustered into three major genetic groups, (i) a group comprised of the pathogenic RHDV strains further separated into viruses related to the prototype RHDV and the antigenic variant RHDVa, (ii) a group comprised of the RCV strain together with the Ashington strain and the 06-11 strain described in this study, and (iii) a group comprised of RCV-A1 strain alone (Fig. 2) . We noticed that the RCV, Ashington and 06-11 viruses showed significant genetic variation from each other and from the RHDV sequences.
Experimental evidence of a replicating non-lethal lagovirus
An experimental study was performed to test whether the 06-11 strain could be transmitted by inoculation or through contact from NP-LV infected rabbits to serologically naïve SPF rabbits without causing disease. Serological analyses using the VP60-RHDV ELISA test confirmed that, at the beginning of the assay, the two SPF rabbits were seronegative and the three domestic rabbits were seropositive with low to moderate titres. The presence of antibodies was detected in the blood sample collected as early as D5 from the SPF rabbit in close contact with the three domestic rabbits (low titre) and in the blood sample collected at D10 from the inoculated SPF rabbit (moderate titre). No sign of RHD was detected during the assay, and at necropsy no lesions were seen. Screening for NP-LV RNA was performed in duodenum samples collected from the five rabbits at the sacrifice. We succeeded in amplifying a DNA fragment of the expected size for all the rabbits (PCR U38-L337). The VP60 sequence determined from the SPF rabbit samples was identical to the sequence of the NP-LV strain 06-11 previously established. Thus, we confirmed that this virus can be experimentally transmitted to SPF rabbits without causing clinical signs or mortality.
Field and experimental evidences of a lagovirus that induces nonprotective antibodies
In "JA" location, a natural RHD outbreak occurred at D19 in one hutch where 10 seropositive rabbits, showing moderate to very high antibody levels at D6 (Table 1) , were kept and fed with grass taken from a RHDV-contaminated area. Nine rabbits died within 4 days. At necropsy typical RHD lesions were observed and all the sampled livers were RHDV-positive by RT-PCR test.
In order to experimentally determine whether the NP-LV antibodies detected by the VP60-RHDV ELISA test conferred crossprotection to rabbits against subsequent infection with RHDV, an infection study was performed on five seropositive rabbits with very high antibody levels ( Table 1) . Three rabbits were challenged with an intramuscular inoculation of a dose of RHDV commonly used to check the efficacy of commercial vaccines and died 2-4 days post-infection. The two non-inoculated rabbits placed in contact in an adjacent cage died 4-6 days post-infection. These rates and timeframes of mortality for inoculated or contact animals are consistent with the expected results following the standard viral challenge on immunologically naïve rabbits. By comparison, vaccinated rabbits exhibiting even low RHDV antibody levels as determined with VP60-RHDV ELISA were shown to be protected against the challenge dose used in this study (Bertagnoli et al., 1996) . At necropsy typical RHD lesions were observed and all the sampled livers were RHDV-positive by RT-PCR test.
Discussion
The observation of a spontaneous serological conversion of rabbits more than 2 months old, i.e., without maternal antibodies and having become sensitive to RHD, showed that an active infection was in progress in the rabbitry. The absence of associated mortality suggested that a non-pathogenic virus serologically related to RHDV was responsible for these seroconversions. A similar overall clinical picture previously led to the characterisation of the RCV in an Italian industrial rabbitry (Capucci et al., 1996) . In the present study, experimental investigation showed that the virus is highly infectious as described for RHDV, but non-lethal for rabbits. We could not assume that it is definitively a non-pathogenic virus since we did not histologically examined the representative organs of died rabbits. Thus, we cannot exclude that histological changes may be evident even in the absence of macroscopic changes. Future histological studies will be necessary to clearly demonstrate the lack of pathogenicity of this virus. However, the name of non-pathogenic has been commonly used to characterise the non-lethal lagoviruses isolated in healthy rabbits such as RCV or RCV-A1 even when no histological studies have been performed.
We also confirmed that, in contrast to the RCV or RCV-A1, the antibodies raised against this strain irrespective of their titre do not protect against RHDV. Indeed, a total of 14 out 15 seropositive rabbits died from RHD, including the nine remained in one of the quarantine locations which died following a natural RHDV infection. In a previous study conducted during a RHDV outbreak in a free-living population of rabbits, we observed that some rabbits died from RHD even if they were seropositive for anti-RHDV antibodies and had expected protective titres (Marchandeau et al., 2005) . Some recent molecular data proving the circulation of closely related NP-LV strains in French wild rabbit populations (unpublished results) are in agreement with the present results. Indeed, it is confirmed the hypothesis initially proposed, i.e., these detectable but non-protective antibodies were induced by an NP-LV infection.
We have identified a lagovirus (06-11 strain), which differs from the RHDV strains in terms of pathogenicity, but also in terms of tissue tropism (small intestine) and sequence of the VP60 capsid protein.
These characteristics are consistent with findings on RCV and RCV-A1. 
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Regarding the VP60 gene sequence, 06-11 is closer to the RCV than to RHDV or RCV-A1, but the highest nucleotide and amino acid identity was with the Ashington strain. The majority of the 06-11 amino acid substitutions are found in the C-terminal half of the VP60 protein which forms the outer shell of the capsid of the caliciviruses (Laurent et al., 1994; Neill, 1992; Prasad et al., 1994) . This part of the RHDV capsid contains the main antigenic regions (Barcena et al., 2004; Capucci et al., 1995; Capucci et al., 1998; Martinez-Torrecuadrada et al., 1998; Meyers et al., 1991) . Within this part, the P2 subdomain which forms an external loop and includes the regions C and E defined by Neill (1992) contains determinants for cell binding, host specificity and strain diversity (Chen et al., 2004; Tan et al., 2006) . The relatively low sequence similarity between 06-11 and pathogenic RHDV strains in the P2 subdomain might explain the differences in tropism and lethality. In addition, following the characterisation of RCV, Lavazza and Capucci (2008b) suggested that the region C of the capsid for RHDV could influence the degree of pathogenicity of the caliciviruses. The description for the first time of a strain that was demonstrated to be non-pathogenic but also to have significant sequence variation within the region C could reinforce the hypothesis that this region takes part in viral pathogenicity. In other respects, Esteves et al. (2008) and more recently Kinnear and Linde (2010) showed a positive selection that occurs in the outer shell of the RHDV VP60 protein and drives amino acid substitutions at some specific sites (named positively selected codons or PSCs) within regions where the main antigenic determinants were described. These authors therefore suggested that variation of a PSC is likely to be related to pathogenicity and virulence. Amino acid differences observed in the 06-11 sequence at some of the identified PSCs (aa 307 and 432), and notably in the region C of the capsid, seems to confirm their importance in the antigenic diversity within the Caliciviridae.
The 06-11 strain represents a new NP-LV clustered into the Ashington lineage and close to RCV. The Ashington strain was supposed to be pathogenic according to Moss et al. (2002) but it has never been implicated in any other recognisable epidemic outbreak in the UK (Forrester et al., 2009 ). Its close relationship with the 06-11 strain could suggest that this strain is non-lethal and experimental confirmation or invalidation of its pathogenicity would be very useful to understand the genetic evolution of these two viruses. Indeed, the phylogenetic tree topology suggested that the RCV and the 06-11/Ashington lineage emerged long before the divergence of the pathogenic RHDV lineage, with the RCV emerging prior to the 06-11/Ashington lineage in agreement with previous published results (Kerr et al., 2009; Moss et al., 2002) . In addition, our results showed a significant genetic variation between 06-11 and Ashington indicating that these two strains may possibly have evolved independently. Regarding the two other divergent Lambay and Pit-WD strains described in the UK (Forrester et al., 2007 (Forrester et al., , 2009 , although only one third of their VP60 sequence is known, results also showed a high genetic variation between 06-11 and these two strains, especially with the latter (only 85.6% amino acid similarity). All these data indicate considerable divergence between these different NP-LV strains. The mean time to the most recent common ancestor (TMRCA) of RHDV and NP-LV strains was estimated to be over 80 (Kinnear and Linde, 2010) or 200 years ago (Kerr et al., 2009 ). In the only study that includes the Ashington strain in its analyses, the mean TMRCAs of the Ashington and Australian RCV-A1 strains fall in the 19 th century (Kerr et al., 2009 ). The authors correlated this time with the date of introduction of domestic European rabbits to Australia and the resulting presence of RCV-A1. However, our phylogenetic results show that the RCV-A1 lineage diverged long prior to the 06-11/ Ashington one. It would be interesting to carry on screening for NP-LV strains in European countries to identify a virus closer to RCV-A1, which would be more likely to be at the source of the Australian virus. These data confirm the circulation of several different nonpathogenic lineages and highlight the extent of diversity within the lagovirus genus. Moreover, among this high diversity, our results show the existence of a gradient of cross-protection between strains. Indeed, whereas we have demonstrated the existence of NP-LV strains, previous studies have shown partial cross-protection between RHDV and RCV-A1 viruses, low titres being non-protective McPhee et al., 2009; Strive et al., 2010) . Cross-protection is complete with RCV (Capucci et al., 1996) or between RHDV viruses as shown by the efficacy of vaccine strains. To better understand RHDV epidemiology in wild populations, besides taking into account factors such as population size and climate Mutze et al., 1998; Parkes et al., 2002) , host genetics (Guillon et al., 2009) , and virulence of viral strains (Fouchet et al., 2009) , we need to determine to what extent NP-LV strains fail to induce protective immunity against RHDV. Indeed, differences of cross-protection might explain the described variability of the impact of RHD on rabbit populations. The existence of non-protective strains as well as the evidence of recombination between strains Forrester et al., 2008) should lead to reconsideration of the interaction between pathogenic and non-pathogenic strains, which is likely to be more complex than previously assumed. Studies are underway to identify the full-length genome sequence of 06-11 strain. Complete molecular data on a non-pathogenic and non-protective lagovirus should enable understanding of RHDV evolution through a comparison with data already available on some RHDVs (Forrester et al., 2008) and on the evolutionarily earlier RCV-A1 lineage (Strive et al., 2009 ).
Materials and methods
Animals
Sixty 10-week-old New Zealand White rabbits showing no apparent sign of disease were placed in quarantine into several hutches in two distinct locations of several kilometres far away each other ("AR" and "JA"; Table 1 Table 2 ), the non-pathogenic Italian RCV and Australian RCV-A1 strains, the UK Ashington strain and the NP-LV 06-11 strain, using the minimum evolution method. Bootstrap values greater than 70% (for 1000 replicates) are given in italics after each node. The French reference European brown hare syndrome virus strain EBHSV-GD (accession number Z69620) was used as an outgroup to root the tree. The RHDV and RHDVa branches are collapsed to highlight the main genogroups. assay in the field as sentinel animals. The rabbits were raised without vaccination against RHDV or myxomatosis in a controlled small rabbitry which had maintained good sanitary conditions for several years. To determine their serological status against RHDV, sera were collected onto blotting paper twice, 1 week apart, at D0 and at D6, and blood samples were screened for the presence of RHDV antibodies. Sera from the seronegative or seropositive with low titre rabbits at D6 were collected again at D13.
To attempt to identify NP-LV viruses, we sacrificed rabbits at the beginning of the seroconversion to collect liver, spleen and small intestine (duodenum) samples. We therefore sacrificed at D13 24 rabbits among those that were seronegative or seropositive with low or moderate antibody titres at D0, and sacrificed at D21 five rabbits that were seronegative or having low titres at D6. The other 31 rabbits were kept in the hutches.
Antibody detection
A VP60-RHDV ELISA based on the detection of a baculovirusexpressed capsid protein (VP60) antigen that self-assembles into virus-like particles (Laurent et al., 1994) was used for semiquantitative measurement of the antibody titres according to the method described in Marchandeau et al. (2005) . A serum was considered to be negative when the ratio sample OD 405 (optical density)/negative control OD 405 was below 3, positive with low titre (+) when the ratio was between 3 and 4, positive with moderate titre (++) when the ratio was between 4 and 6, positive with high titre (+++) when the ratio was between 6 and 8, and positive with very high titre (++++) when the ratio was above 8. As this ELISA does not enable discrimination of antibodies due to RHDV infection from those due to RHDV-like infections (Marchandeau et al., 2005) , some positive sera (n= 24) were also screened with a competitive ELISA (cELISA) and anti-isotype ELISA tests (Capucci et al., 1997) as described in Cooke et al. (2000 Cooke et al. ( , 2002 and Lavazza and Capucci (2008a) . The cELISA recognises an external epitope specific to RHDV (Capucci et al., 1997) . This test using a monoclonal antibody is considered as the standard, reference serological test for RHD (Lavazza and Capucci, 2008a) . The anti-isotype ELISA tests detect IgM, IgG and IgA specific to RHDV. They are used to interpret field serology and to determine the immunological status of rabbits (Lavazza and Capucci, 2008b; Cooke et al., 2002) . The use of these different tests makes it possible to detect a large range of antibodies raised against rabbit lagoviruses and to discriminate antibodies raised against RHDV from those raised against other rabbit lagoviruses.
RT-PCR and sequence analysis
Each frozen liver sample was thawed and 100 μl of the obtained exudate was collected. For the other tissue samples (duodenum and spleen), 30 mg was homogenised using a mixer-mill disruptor (TissueLyser, QIAGEN). RNAs were extracted using the RNeasy Mini kit (QIAGEN) and viral RNAs were reverse transcribed using oligo-dT (Invitrogen) as a primer and SuperScript™ II Reverse Transcriptase (Invitrogen).
For the initial screening, several pairs of RHDV primers for polymerase chain reaction (PCR) amplification were used, among which were three pairs previously defined to amplify overlapping genomic regions of the gene encoding the VP60 (Le Gall-Reculé et al., 2003) . Two successive amplifications with the same PCR primers using the AmpliTaq Gold® DNA polymerase (Applera Applied Biosystems) were necessary to obtain sufficient quantities of DNA to allow their sequencing. The amplified PCR products were visualised by electrophoresis on agarose gel and purified (UltraClean™ 15 DNA Purification Kit, Mo Bio Laboratories) prior to sequencing. The DNA sequence was determined twice in both directions by the dye terminator method (ABI PRISM DyeTerminator Cycle Sequencing Ready Reaction kit, Applera Applied Biosystems) on an ABI 373XL automatic DNA sequencer (Applera Applied Biosystems) with the PCR primers and sequencing primers (Le Gall-Reculé et al., 2003) . To confirm the assembled VP60 gene sequence, positive cDNAs were subjected to one run of full-length VP60 PCR amplification using a specific primer pair designed from the preliminary NP-LV VP60 gene sequences we obtained. A high-fidelity DNA polymerase (Expand High Fidelity PLUS PCR System, Roche Applied Science) was used. The DNA sequence was determined using PCR and sequencing primers as described above (primer sequences available upon request). The deduced amino acid sequences of the VP60 gene were obtained using the software available on the Biosupport website. Multiple amino acid sequence alignments were generated by the CLUSTALW method using the NPS website. Following RHDV infections, RNA was extracted from liver exudates using a commercial kit (RNeasy Mini kit, QIAGEN) and tested for RHDV RNA by RT-PCR as described by Le Gall-Reculé et al. (2003) . Screening for NP-LV RNA was performed from duodenum samples as described in the previous paragraph, except that RNA was extracted in a preliminary step with TRIzol® Reagent (Invitrogen) before the use of "RNeasy" columns to increase the sensitivity. For the screening of positive samples, we used a pair of PCR primers ("U38" 5' CAGCGGGCACTGCTACCACAGCATC 3' and "L337" 5' GAAGCGAAACTG-CATGCCACCRGCCCA 3') derived from the one (Rab1b-Rab2) defined by Tanja Strive (CSIRO, Australia) who kindly provided us with the sequences before their publication (Strive et al., 2009) . Then, the fulllength VP60 PCR amplification was performed.
Phylogenetic analyses
Phylogenetic relationships were inferred using entire sequences of the capsid protein VP60 gene available in databases from some representative pathogenic RHDV and the antigenic variant RHDVa (Capucci et al., 1998) , the non-pathogenic Italian RCV strain and the non-pathogenic lagovirus RCV-A1 recently characterised in Australia. We also included the sequence of the divergent Ashington strain from the UK since it is almost complete (95% of the gene). The accession number, country of origin and year of collection of the 36 sequences are listed in Table 2 . The sequence of the French reference European brown hare syndrome virus (EBHSV) strain EBHSV-GD (accession number: Z69620 (Le ) was used as an outgroup to root the trees. Phylogenetic analyses were conducted using MEGA software version 3.1 (Kumar et al., 2004) for phenetic and cladistic characterisation. Multiple sequence alignments were generated by the CLUSTALW method. For the phenetic analysis, the Minimum Evolution (ME) method was implemented with the Kimura 2-parameter model including transition and translation substitutions. The search for the ME tree was implemented with the closeneighbour-interchange option and the Neighbour-joining algorithm was used to generate the initial tree. For the cladistic method, Maximum Parsimony (MP) was used and the search for the MP tree was implemented with the close-neighbour-interchange algorithm. For the two methods, codon positions included were the 1st and the 2nd, and the pairwise deletion option was selected. The topology of trees was evaluated by 1000 bootstrap analyses. Majority-rule consensus trees were determined by the CONSENSE program and were drawn using MEGA software version 3.1.
Experimental studies of viral transmission and of protection against RHDV infection
Two experimental studies were performed under negative pressure in rooms at BSL2 experimental facilities with filtered air according to biosafety and bioethical procedures, under the authorization of animal experimentation number 22-24 delivered by the local director of veterinary services on behalf of the prefect of Côtes d'Armor department.
First, in order to study the transmission route and lethality of the 06-11 strain, two 10-week-old specific-pathogen-free (SPF) commercial New Zealand White rabbits were used. To test the lethality of the virus isolated in the rabbitry, one SPF rabbit was inoculated by the oro-nasal route with filtered (0.22 μm) supernatant of a pool of duodenum samples from which RHDV-like RNAs had been characterised. In order to study the possibility of viral transmission through contact, the other SPF rabbit was placed in a cage with three 9-weekold healthy rabbits taken from the rabbitry. Blood samples were collected onto blotting paper from the five rabbits at the beginning of the assay (D0), then twice 5 days apart (D5 and D10) and at the sacrifice (D14). Detection of antibodies was performed using the VP60-RHDV ELISA test. Daily observations for morbidity (asthenia, anorexia, respiratory and nervous signs) and mortality were performed. Surviving animals were killed humanely and examined for macroscopic lesions. Duodenum and liver samples were collected for virological analyses.
Second, in order to determine whether the detected 06-11 antibodies conferred cross-protection to rabbits against subsequent RHDV infection, five rabbits exhibiting very high titres of antibodies were selected for an experimental challenge (Table 1) . They were split into two groups: (i) three rabbits were challenged with a standardised intramuscular inoculation of 10 3 LD 50 of RHDV reference strain isolated in 1988 in France and (ii) two rabbits were placed in an open wire-meshed cage adjacent to that of inoculated rabbits that allowed direct contact between the rabbits to favour infection by a natural route. Daily observations for morbidity (asthenia, anorexia, respiratory and nervous signs) and mortality were performed. Dead rabbits were examined for macroscopic lesions and liver samples were collected for virological analyses.
Nucleotide sequence accession number
The nucleotide sequence of the NP-LV strain 06-11 is available in databases under the GenBank/EMBL accession number AM268419.
